Key result
Colchicine cuts MI risk ~36% and reduces stroke in CAD but increases GI side effects.
Why the study?
Although colchicine seems to reduce ischemic events in coronary artery disease, there is equipoise regarding its safety and impact on mortality.
Does colchicine reduce myocardial infarction, stroke, and mortality in patients with coronary artery disease?
Meta-Analysis (n=13,125)
Does colchicine reduce myocardial infarction, stroke, and mortality in patients with coronary artery disease?
Effect estimate: OR 0.64 (95% CI 0.46-0.90)
p-value: p=0.01
Colchicine reduces the risk of myocardial infarction and stroke in patients with coronary artery disease, though it increases gastrointestinal side effects and does not improve mortality.
No takes yet. Share an insight, caveat, or question.
Colchicine merits consideration for CAD secondary prevention to lower MI and stroke; extends anti-inflammatory evidence despite neutral mortality and GI effects.
Kofler et al. (2021) conducted a meta-analysis in coronary artery disease (n=13,125). Colchicine vs. placebo/standard therapy was evaluated on myocardial infarction (OR 0.64, 95% CI 0.46-0.90, p=0.01). Colchicine reduced the risk of myocardial infarction (OR 0.64; 95% CI 0.46-0.90; P=0.01) and stroke/TIA in patients with CAD, but did not affect mortality and increased gastrointestinal side effects.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: